美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Biotech ETF

154.03

-3.5700-2.27%

盤前：154.480.4500+0.29%04:43 EDT

成交量：1,130.06萬

成交額：17.39億

市值：105.01億

市盈率：8.45

高：157.53

開：157.08

低：152.63

收：157.60

52周最高：169.89

52周最低：93.26

股本：6,817.50萬

流通股本：6,817.50萬

量比：1.47

換手率：16.58%

股息：0.57

股息率：0.37%

每股收益(TTM):18.23

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

政策解答！事關泰興職工醫保退休待遇

醫療保健板塊市場綜述：諾華、樂敦、手套製造業與IHH等熱點解析

醫療保健板塊動態：市場快訊綜述

內蒙古：圍繞生物食品、生物醫藥、生物化工等重點領域加快實施生物製造產業重點項目

醫療保健板塊動態：市場快訊綜述

百龍創園在昆明成立生物科技公司

美國總統特朗普：我們將直接向美國人發放資金，用於購買醫療保險，並讓他們保留剩餘部分。

健康產業綜合報道：市場快訊

醫療保健板塊市場綜述：多空交織下的投資機遇

醫療保健板塊市場快訊綜述

國泰海通證券累計投資超60家生物醫藥優質企業，投資總規模突破35億元

南方财经网

傳私募股權TPG(TPG.US)擬出售醫療保健軟件公司Lyric 估值或達50億美元

傳私募股權TPG(TPG.US)擬出售醫療保健軟件公司Lyric 估值或達50億美元

TPG考慮以50億美元出售醫療保健軟件公司Lyric

TPG探索出售醫療保健軟件公司Lyric

醫療板塊市場綜述：多空觀點交鋒

醫療保健板塊動態：市場快訊匯總

北京生物醫藥保險共保體正式成立完善創新醫藥產業保障

北京生物醫藥保險共保體正式成立完善創新醫藥產業保障

央视新闻客户端

醫療保健板塊動態：市場快訊綜述

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/XBI/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"SPDR S&P Biotech ETF","latestPrice":154.03,"timestamp":1789502400000,"preClose":157.6,"halted":0,"volume":11300561,"hourTrading":{"tag":"盘前","latestPrice":154.48,"preClose":154.03,"latestTime":"04:43 EDT","volume":1341,"amount":207358.23996,"timestamp":1789548206980,"change":0.45,"changeRate":0.002922,"amplitude":0.005363},"delay":0,"changeRate":-0.02265228426395935,"floatShares":68175000,"shares":68175000,"eps":18.23,"marketStatus":"盤前交易","change":-3.57,"latestTime":"09-16 05:08:56 EDT","open":157.08,"high":157.53,"low":152.63,"amount":1738536841.14598,"amplitude":0.031091,"askPrice":154.8,"askSize":400,"bidPrice":154,"bidSize":400,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":154.03,"sharesOutstanding":63325000,"nav":157.586874,"aum":10743485169.21,"dividendRate":0.0037,"bidAskSpread":0.000306,"preHourTrading":{"tag":"盘前","latestPrice":154.48,"preClose":154.03,"latestTime":"04:43 EDT","volume":1341,"amount":207358.23996,"timestamp":1789548206980,"change":0.45,"changeRate":0.002922,"amplitude":0.005363},"postHourTrading":{"tag":"盘后","latestPrice":154.1,"preClose":154.03,"latestTime":"19:59 EDT","volume":217310,"amount":33483251.403,"timestamp":1789516796776,"change":0.07,"changeRate":0.000454,"amplitude":0.001883},"volumeRatio":1.4749354161726091,"optionData":{"bulkOrders":[{"symbol":"XBI","call":false,"expireDate":1792123200000,"strike":"150.0","timestamp":1789502340274,"price":3.85,"volume":15000,"amount":5775000,"type":"+"},{"symbol":"XBI","call":false,"expireDate":1789704000000,"strike":"158.0","timestamp":1789502340274,"price":4.52,"volume":15000,"amount":6780000,"type":"-"}]},"impliedVol":0.319,"impliedVolPercentile":0.62},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":68175000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.4749354161726091,"shares":68175000,"dividePrice":0.5699,"high":157.53,"amplitude":0.031091,"preClose":157.6,"low":152.63,"week52Low":93.26,"pbRate":"--","week52High":169.89,"institutionHeld":0.8511,"latestPrice":154.03,"eps":18.23,"divideRate":0.0037,"volume":11300561,"delay":0,"ttmEps":18.23,"open":157.08,"prevYearClose":121.93,"prevWeekClose":156.2,"prevMonthClose":162.5,"prevQuarterClose":158.25,"fiveDayClose":161.93,"twentyDayClose":159.53,"sixtyDayClose":140.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XBI","amount":0.138094,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.031139,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.03704,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667851836","title":"政策解答！事關泰興職工醫保退休待遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2667851836","media":"泰兴发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667851836?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 10:31","pubTimestamp":1789266660,"startTime":"0","endTime":"0","summary":"我市职工医保退休待遇核定政策解答来了一办理医保退休待遇核定需达到哪些条件？举个例子：2026年泰兴一单位男职工，已交200个月，缴费基数4952元，那么他办理退休时需一次性补缴的医疗保险费用为*10%*4952=49520元；如他有2 年的视同缴费年限，那么他办理退休时需一次性补缴的医疗保险费用为*10%*4952=37635.20元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-13/doc-inirrxsc0610142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","XLV","BK4581","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147535317","title":"醫療保健板塊市場綜述：諾華、樂敦、手套製造業與IHH等熱點解析","url":"https://stock-news.laohu8.com/highlight/detail?id=1147535317","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147535317?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:56","pubTimestamp":1789160215,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场快讯速览——本系列报道聚焦于行业动态，为您捕捉关键信息。0110 ET - 野村证券分析报告称，得益于核心品牌在日本及海外市场的强劲销售势头，乐敦制药本财年业绩有望超越其全年指引。花旗预计，这家医疗器械制造商\"中期内可实现可持续的两位数盈利增长，且相比澳新其他医疗股，受消费端波动的影响更小。该股当前下跌1.3%，报43.37新西兰元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","XLV","LABU","BK4581","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183095065","title":"醫療保健板塊動態：市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1183095065","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183095065?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 00:22","pubTimestamp":1789143768,"startTime":"0","endTime":"0","summary":"最新一期的医疗保健行业市场快讯已发布，涵盖多家业内重要企业的动态。本综述仅在道琼斯通讯社于美东时间4:20、12:20及16:50独家刊出。美东时间1930 - 花旗对斐雪派克医疗持看多立场，认为该公司为投资者提供了增长性与交付可靠性兼备的投资标的。花旗预计，这家医疗器械制造商“中期内将实现可持续的两位数盈利增长，且相较澳新地区其他医疗类股票，其对消费端波动的敞口更低”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4581","LABU","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540291","title":"內蒙古：圍繞生物食品、生物醫藥、生物化工等重點領域 加快實施生物製造產業重點項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540291","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666540291?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:19","pubTimestamp":1789118364,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["XBI","BK4581","161726","399441","159151","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139785537","title":"醫療保健板塊動態：市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1139785537","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139785537?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 16:23","pubTimestamp":1789115000,"startTime":"0","endTime":"0","summary":"医疗保健板块最新市场快讯，涵盖多只个股动态与行业趋势。这些信息分别在美东时间4:20、12:20和16:50通过道琼斯通讯社独家发布。2330 GMT——费雪派克医疗保健获得花旗的看涨背书，后者认为该公司既能提供增长潜力，又具备可靠的业绩兑现能力。花旗预计这家医疗器械制造商“中期内将实现可持续的两位数盈利增长，且相较于澳新地区的其他医疗保健类股票，其对消费者动态的敞口较低。”该股现报43.37新西兰元，下跌1.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XBI","BK4585","XLV","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510878","title":"百龍創園在昆明成立生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510878?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:32","pubTimestamp":1789093959,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","SYNB","XBI","BK4588","BK4585","GDOC","IEIH","AGNG","IBBJ","LNGR","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517011","title":"美國總統特朗普：我們將直接向美國人發放資金，用於購買醫療保險，並讓他們保留剩餘部分。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517011","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517011?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:28","pubTimestamp":1789093737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LABU","XBI","BK4581","XLV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114631909","title":"健康產業綜合報道：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1114631909","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114631909?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 04:52","pubTimestamp":1789073579,"startTime":"0","endTime":"0","summary":"最新一期聚焦健康产业的市场快讯，于美东时间4:20、12:20及16:50通过道琼斯通讯社首发。当日，该公司股价下滑4.2%，收于8.72港元。马来西亚橡胶产品行业的盈利动能似乎正趋于稳定，而近年来股价的大幅回调使得估值更具吸引力，兴业投行分析师Andrew Lim在一份报告中如此表示。有鉴于此，兴业投行将该国橡胶产品行业的评级从“减持”上调至“增持”，并将贺特佳视为其首选标的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","BK4581","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110355096","title":"醫療保健板塊市場綜述：多空交織下的投資機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=1110355096","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110355096?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 00:22","pubTimestamp":1789057364,"startTime":"0","endTime":"0","summary":"最新一轮医疗保健板块市场动态已出炉，涵盖多家亚洲主要医疗企业的股价走势、业绩展望与投资评级调整。市场反应方面，该股当日下跌4.2%，报收8.72港元。综合来看，亚洲医疗健康领域正呈现出多元化的投资叙事：从中国药企的临床数据催化，到新加坡医疗运营商的估值修复逻辑，再到印度医院的扩张故事以及马来西亚橡胶制品板块的估值重估，各细分赛道均蕴藏着不同的机遇与挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4588","XLV","BK4585","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143873044","title":"醫療保健板塊市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1143873044","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143873044?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:23","pubTimestamp":1789028599,"startTime":"0","endTime":"0","summary":"DBS集团研究部的Mark Kong与Nico Chen在一份报告中指出，石药集团未来两个月即将公布的临床数据演示，可能成为其股价近期走势的关键催化剂。分析师认为，公司主动参与数据发布，彰显了其对数据的充分信心。目前石药集团的估值约为2027年预测市盈率的18倍，较同行平均水平折价约28%，这为投资者提供了一个颇具吸引力的入场时机。DBS重新覆盖石药集团，给予\"买入\"评级，目标价定为13.70港元。该股今日下跌4.2%，报8.72港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XBI","BK4588","XLV","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666655765","title":"國泰海通證券累計投資超60家生物醫藥優質企業，投資總規模突破35億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666655765","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666655765?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:08","pubTimestamp":1789016880,"startTime":"0","endTime":"0","summary":"南方财经9月10日电，9月8日至9日，国泰海通2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛在上海召开。国泰海通党委书记、董事长朱健在致辞中表示，国泰海通持续构建“投资+投行+投研”三投联动的立体化服务体系，深度覆盖生物医药企业全生命周期，以一站式综合金融服务，精准匹配产业发展与企业成长的多元需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870433953.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870433953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK4588","03441","PRTO","BK0188","BK0276","BK1564","BK4581","BK0184","399441","161027","161726","BK0028","XBI","BK1147","02611","BK0201","601211","BK4585","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554879","title":"傳私募股權TPG(TPG.US)擬出售醫療保健軟件公司Lyric 估值或達50億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554879","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 10:30","pubTimestamp":1789007455,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PRVT","IGM","XLV","BK4585","NOBL","BK4581","VHT","LABU","PSP","XBI","BK4588","BK4550","CGVV","AAUM","BUYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554821","title":"傳私募股權TPG(TPG.US)擬出售醫療保健軟件公司Lyric 估值或達50億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554821","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554821?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 10:30","pubTimestamp":1789007455,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据知情人士透露，私募股权TPG正在探索出售医疗保健行业软件公司Lyric。他们提醒称，目前无法保证出售流程最终会促成Lyric交易。TPG于2022年以约22亿美元收购ClaimsXten。TPG于次年将该公司重新命名为Lyric。尽管具体增幅并未披露，但TPG表示，Lyric受益于AI的部署，而其拥有丰富数据集的业务模式将进一步放大这些收益。规模较小的上市同行Claritev股价在2025年9月至今年5月期间暴跌80%，原因是投资者担心AI会颠覆软件公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["XBI","AAUM","IGM","NOBL","BK4550","LABU","PRVT","CGVV","BUYO","BK4581","PSP","BK4585","VHT","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666955978","title":"TPG考慮以50億美元出售醫療保健軟件公司Lyric","url":"https://stock-news.laohu8.com/highlight/detail?id=2666955978","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666955978?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:48","pubTimestamp":1789004922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LABU","BK4588","XBI","NOBL","BK4550","BK4581","IGM","VHT","CGVV","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666553284","title":"TPG探索出售醫療保健軟件公司Lyric","url":"https://stock-news.laohu8.com/highlight/detail?id=2666553284","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666553284?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 07:38","pubTimestamp":1788997084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CGVV","LABU","XBI","NOBL","VHT","BK4585","IGM","BK4581","BK4550","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123618563","title":"醫療板塊市場綜述：多空觀點交鋒","url":"https://stock-news.laohu8.com/highlight/detail?id=1123618563","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123618563?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 04:53","pubTimestamp":1788987194,"startTime":"0","endTime":"0","summary":"最新一期医疗板块市场快讯已发布，涵盖多家制药巨头的最新动态与分析师观点。本轮快讯于美国东部时间4:20、12:20和16:50在道琼斯通讯社独家刊出。**1107 ET**——加拿大皇家银行资本市场分析师在研报中指出，近期临床试验受挫意味着诺华制药必须在剩余管线产品的市场推广上做到近乎完美，抑或寻求并购交易。RBC给予该股\"与板块持平\"评级，目标价定为120瑞士法郎。诺华股价微跌0.3%，报111.44法郎。协和麒麟周二表示，该研究未能达到主要终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","LABU","XLV","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191167112","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1191167112","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191167112?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 00:37","pubTimestamp":1788971848,"startTime":"0","endTime":"0","summary":"1107 GMT - 加拿大皇家银行资本市场分析师在研究报告中指出，近期临床试验受挫意味着诺华必须近乎完美地将其余管线产品推向市场，或寻求交易合作，但这家瑞士制药商不应操之过急。\"他们补充称，心血管药物pelacarsen和神经肌肉药物del-desiran的失败提高了诺华管线的门槛，因为这两款药物本是抵消即将到来的专利到期所造成销售损失的重要候选产品。RBC首次覆盖该股，给予\"与行业一致\"评级，目标价定为120瑞士法郎。该股下跌0.3%，报111.44法郎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","BK4588","XBI","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538245","title":"北京生物醫藥保險共保體正式成立 完善創新醫藥產業保障","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538245?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:19","pubTimestamp":1788956341,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4585","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533350","title":"北京生物醫藥保險共保體正式成立 完善創新醫藥產業保障","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533350","media":"央视新闻客户端","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533350?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956280,"startTime":"0","endTime":"0","summary":"记者从北京市科委、中关村管委会了解到，北京生物医药保险共保体于近日正式成立，这是继全国首个商业航天保险共保体落地之后，北京在科技保险领域的又一重要实践。北京生物医药保险共保体的成立，将有效分散创新药械初创企业研发风险，也为投资机构分担投资不确定性，进一步引导更多社会风险资本投向创新药械管线的临床研究环节，打通金融支持生物医药成果转化的关键环节。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfums3623315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4581","399441","XBI","BK4585","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104370787","title":"醫療保健板塊動態：市場快訊綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1104370787","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104370787?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:22","pubTimestamp":1788942151,"startTime":"0","endTime":"0","summary":"涵盖医疗保健板块的最新市场快讯，于美国东部时间4:20、12:20及16:50在道琼斯通讯社独家发布。该分析师表示，del-desiran原本是近期120亿美元收购Avidity的首个有力佐证。股价下挫4.7%，报2,251.0日元。2239 GMT——Petra Capital表示，由于美国食品药品监督管理局未对Echo IQ用于检测心力衰竭的工具EchoSolv HF给予批准，该公司股价今日可能遭遇抛售。FDA出具了“非实质性等同”判定。业界不乏企业在解决相关问题后最终获得FDA批准的案例。该机构将该股评级从“持有”下调至“卖出”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XBI","BK4585","BK4581","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}